Review: The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs)

被引：59
|
作者：
Ke, Wanhai [1 ]
Zhang, Li [2 ]
Dai, Yan [1 ]
机构：
[1] Chinese Acad Med Sci, Fuwai Hosp, Peking Union Med Coll, Arrhythmia Ctr, Beijing, Peoples R China
[2] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Peking Union Med Coll, Resp Med Dept, Beijing 100730, Peoples R China
来源：
THORACIC CANCER | 2020年 / 11卷 / 04期
关键词：
Interleukin-6; non-small cell lung cancer; immune related adverse events; CIRCULATING LEVELS; GROWTH-FACTOR; TOCILIZUMAB; INTERLEUKIN-6; SURVIVAL; RECEPTOR; MANAGEMENT; ANTIBODY; DISEASE; MARKERS;
D O I：
10.1111/1759-7714.13341
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IL-6 is a cytokine that plays an important role in response to injury or infection and is a promising biomarker for predicting poor prognosis and therapeutic targets in non-small cell lung cancer (NSCLC). This article reviews the biochemical mechanism, function and genotype of IL-6, and summarizes the diagnostic and prognostic value of IL-6 level. Anti-IL-6 therapy does not affect the effect of immunocheckpoint inhibitors (ICIs), but enhances its anticancer function, which may be the treatment option for immune-related adverse events (irAEs) in the future. Therefore, IL-6 may be a therapeutic target for the treatment of NSCLC.
引用
收藏
页码：835 / 839
页数：5
相关论文
共 50 条
  • [1] Association of immune-related adverse events (irAEs) and immunotherapy (IT) benefit in advanced non-small cell lung cancer (NSCLC)
    Saavedra Serrano, C.
    Barquin Garcia, A.
    Corral de la Fuente, E.
    Serrano Domingo, J. J.
    Albarran Artahona, V.
    Martin Huertas, R.
    Gomez Rueda, A.
    Olmedo Garcia, M. E.
    ANNALS OF ONCOLOGY, 2019, 30
  • [2] Role of Immune-Related Adverse Events (irAEs) and Albumin in Non-Small-Cell Lung Cancer (NSCLC)
    Bawek, S.
    Kalvapudi, S.
    Vedire, Y.
    Pachimatla, A.
    Jain, P.
    Yendamuri, S.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S612 - S613
  • [3] Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)-Their Incidence, Management, Multiorgan irAEs, and Rechallenge
    Vaddepally, Raju
    Doddamani, Rajiv
    Sodavarapu, Soujanya
    Madam, Narasa Raju
    Katkar, Rujuta
    Kutadi, Anupama P.
    Mathew, Nibu
    Garje, Rohan
    Chandra, Abhinav B.
    BIOMEDICINES, 2022, 10 (04)
  • [4] Serum proteomic scores for understanding the mechanisms of immune-related adverse events (irAEs) in non-small cell lung cancer
    Davis, Andrew A.
    Park, Jonghanne
    Kim, Leeseul
    Gim, Gahyun
    Iams, Wade T.
    Oh, Michael S.
    Lentz, Robert W.
    Roder, Heinrich
    Roder, Joanna
    Asmellash, Senait
    Net, Lelia
    Grigorieva, Julia
    Mohindra, Nisha
    Villaflor, Victoria
    Chae, Young Kwang
    CANCER RESEARCH, 2020, 80 (16)
  • [5] Immune-related adverse events (irAEs) and survival (OS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with immunotherapy
    Melian Sosa, M.
    Puchades, C.
    Mendez, J. A.
    Torres, A.
    Rodrigo, C.
    Gimeno, G.
    Rama, E.
    Martinez-Castillo, A.
    Caballero Daroqui, J.
    Gomez Codina, J.
    Juan-Vidal, O.
    Lorente, D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] POTENTIAL ROLE OF SERUM PROTEOME IN PREDICTING IMMUNE-RELATED ADVERSE EVENTS FROM IMMUNOTHERAPY IN NON-SMALL CELL LUNG CANCER
    Kim, Leeseul
    Chae, Young Kwang
    Lee, Dong-Uk
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A29 - A29
  • [7] Immune-related adverse events (IrAEs) as a predictor of response to immunotherapy in patients with lung cancer
    Sanchez Becerra, M. V.
    Martinez-Cabanes, R.
    Gonzalez-Lopez, A.
    Zhan-Zhou, E.
    Sotelo, V.
    Esteban, M.
    Robles, T.
    Camara, J. C.
    Cardena, A.
    Hernando, S.
    Hurtado, A.
    Moreno, D.
    Olier, C.
    Mielgo Rubio, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S808 - S809
  • [8] Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer
    Burke, Michael
    Rashdan, Sawsan
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [9] Impact of immune-related adverse events (irAE) on overall survival (OS) in patients treated with immunotherapy for non-small cell lung cancer (NSCLC).
    Owen, Dwight Hall
    Wei, Lai
    Villalona-Calero, Miguel Angel
    Bertino, Erin Marie
    He, Kai
    Shields, Peter G.
    Carbone, David P.
    Otterson, Gregory Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Advanced lung cancer inflammation index (ALI) association with increased risk of immune-related adverse events (irAEs) among non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy
    Bhat, V.
    Millward, M.
    Gray, E. S.
    Abed, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1049 - S1049
12345